Our Investors
Our investors share our vision and passion and bring deep expertise and experience in developing promising companies such as Artios.
Artios raised $153 million (£110 million) in July 2021 through a Series C round. The oversubscribed financing was led by Omega Funds and TCG X and included Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments LP, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital. The new investors joined existing investors Arix Bioscience plc, SV Health Investors, Andera Partners, EQT Life Sciences, M Ventures, Pfizer Ventures, IP Group plc, and Novartis Venture Fund.
In August 2018, Artios raised $84 million (£65 million) in a Series B financing. The financing was led by Andera Partners and LSP, with participation by Pfizer Ventures and Novartis Bioventures as well as existing shareholders AbbVie Ventures, Arix Bioscience, IP Group, Merck Ventures and SV Health Investors.
The financing follows a $33 million (£25 million) Series A fundraise that was completed in September 2016.
